SELECTION AND SWITCHING OF GENETICALLY ENGINEERED BIOLOGICAL AGENTS IN TREATMENT OF JUVENILE ARTHRITIS

2018 ◽  
Vol 97 (3) ◽  
pp. 52-61
Author(s):  
E.S. Zholobova ◽  
◽  
A.K. Ignatova ◽  
N.G. Seylanova ◽  
A.P. Golubeva ◽  
...  
Keyword(s):  
Biological Agents ◽  
Genetically Engineered ◽  
Juvenile Arthritis

scholarly journals Treatment with Genetically Engineered Biological Agents: Efficacy and Safety of Changeover

2014 ◽  
Vol 13 (1) ◽  
pp. 33-50
Author(s):  
A.A. Baranov ◽  
◽  
E.I. Alexeeva ◽  
S.I. Valieva ◽  
T.M. Bzarova ◽  
...  
Keyword(s):  
Biological Agents ◽  
Genetically Engineered ◽  
Efficacy And Safety

scholarly journals Efficacy of genetically engineered biological agents in the treatment of uveitis associated with rheumatic diseases in children

2012 ◽  
Vol 0 (4) ◽  
pp. 91 ◽  
Author(s):  
V V Neroyev ◽  
L A Katargina ◽  
E V Denisova ◽  
A V Starikova ◽  
N V Lyubimova
Keyword(s):  
Rheumatic Diseases ◽  
Biological Agents ◽  
Genetically Engineered

scholarly journals PHARMACOECONOMIC SUBSTANTIATION OF APPLICATION OF GENETICALLY ENGINEERED BIOLOGICAL AGENTS IN OUT-PATIENT CONDITIONS

2016 ◽  
Vol 9 (1) ◽  
pp. 39-48
Author(s):  
O. Yu. Korennova ◽  
L. V. Shukil' ◽  
S. N. Mal'tsev ◽  
I. A. Klinyshkov ◽  
N. M. Leganova ◽  
...  
Keyword(s):  
Biological Agents ◽  
Genetically Engineered

scholarly journals Early administration of genetically engineered biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An experts’ opinion

2020 ◽  
Vol 48 (6) ◽  
pp. 422-436
Author(s):  
D. I. Abdulganieva ◽  
A. L. Bakulev ◽  
E. A. Belousova ◽  
A. V. Veselov ◽  
T. V. Korotaeva ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Inflammatory Diseases ◽  
Early Stage ◽  
Biological Agents ◽  
Genetically Engineered ◽  
Timely Initiation ◽  
Immune Mediated ◽  
Bowel Diseases ◽  
Initiation Of Therapy ◽  
Definition Of

Psoriasis (Ps), psoriatic arthritis (PsA), and inflammatory bowel diseases (IBDs) are characterized by a  progressive course and commonly result in disability. Therefore, their early diagnosis with the assessment of a  clinical phenotype and unfavorable prognostic factors and the timely initiation of therapy are important. The paper provides the expert consensus on the definition of the early stage of Ps, PsA, and IBDs, their treatment goals and main unfavorable prognostic factors. It also gives the rationale for the early use of biological agents in patients with immune-mediated inflammatory diseases.

Sign in / Sign up

Export Citation Format

Share Document